# Allergy Therapeutics plc Q&A with Zeus Capital’s Director of Healthcare Research (LON:AGY)

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-plc-qa-zeus-capitals-director-healthcare-research/412724056
- Published: 2017-02-17T10:58:49+00:00
- Author: Amilia Stone

**Zeus Capital** Director of Healthcare Research Dr Gary Waanders caught up with
DirectorsTalk for an exclusive interview to discuss **Allergy Therapeutics plc**(
[LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l))

 

**Q1: Now, Allergy Therapeutics announced today that it has obtained approval to
begin a Phase I clinical trial of its Acarovac MPL vaccine in Spain, what’s the 
product designed to do Gary?**

**A1**: It’s essentially for the treatment of house dust mite allergy and so Acarovac
MPL is an enhanced version of the company’s existing vaccine Acarovac Plus and this
is currently used as a named patient product for the treatment of allergies caused
by house dust mites. House dust mite allergy is a common problem in many countries,
including the US and Europe, and is growing in accordance in certain Asian countries
like China. House dust mite allergies typically allergic rhinitis causes year-round
sneezing, runny nose, itchy eyes and so, the usual signs of allergic rhinitis, whilst
these symptoms can adversely impact day to day life the bigger concern is that this
allergy can progress to a more serious condition known as allergic asthma, which
can be life-threatening.

So, Acarovac MPL takes the strengths of the existing Acarovac Plus product and enhances
this through the addition of MPL which is the company’s vaccine adjuvant and an 
adjuvant is like an accelerator for immune responses. MPL improves the performance
of vaccines and it is used in the company’s Pollinex Quattro range of vaccines for
seasonal allergies such as hay fever caused by pollens. So, by treating allergic
individuals with the Acarovac MPL the company hopes to safely and effectively induce
a rapid reduction in the symptoms of house dust mite allergy and do this using many
fewer injections than conventional injected vaccines for these sorts of allergies.

 

**Q2: What does the CTA clearance mean for the product’s development?**

**A2**: Ordinarily, there’s considerable work involved in gaining clearance from
the regulators to take new products into clinical trials. So, before such a clearance
is granted, companies have to demonstrate that such a product will be safe, that
there are reasonable grounds to believe that it will be effective and that the product
can be consistently produced according to the high standards required for pharmaceuticals
so that’s GMP manufacturing.

For Allergy, this is a relatively straight forward thing because it already uses
different components of these vaccines in some of its existing vaccines so allergoid
from house dust mite is already included in Acarovac Plus. The other key components
of this vaccine so microcrystalline tyrosine or MCT and the MPL itself are also 
used on a fairly regular basis in the products sold throughout Europe by Allergy
Therapeutics. So, assuming successful study, the vaccine will require further trials
in order to obtain the full regulatory approval for commercial sales, we believe
that, with favourable results, such an approval might be possible in 2023 which 
seems like a long way away. In the meantime, assuming this study gets positive results,
that will enable Allergy Therapeutics to launch the vaccine and sell it on a named
patient basis similar to the Acarovac Plus but this would be an enhanced version.

 

**Q3: Now, you’ve mentioned that house dust mite allergy is a relatively common 
allergy, so if we’re talking of a fully approved vaccine, what sort of sales do 
you think might be possible for Allergy Therapeutics?**

**A3**: In our usual mode of conduct here, we’ve modelled sales for the products
following a launch which we estimate could be in 2024 in the USA and Europe so there’s
still roughly 6 or 7 years to go before it might complete that development for full
regulatory approval. So, from that point of launch to peak sales, as we refer, we
think which might occur in 2030, we believe sales could exceed roughly $500 million
with $200 million of those in Europe and $300,000 in the US. Clearly, that’s a long
way off but in the meantime the product would be available on a named patient basis
so the company would be able to provide the product for specific patients if a doctor
prescribes it.

Share on:
